title: Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study.
abstract: The Third National Wilms' Tumor Study sought to reduce treatment for low-risk patients and find better chemotherapy for those at high risk for relapse. Eligible patients (1439) were randomized according to stage (I-IV) and histology (favorable [FH] or unfavorable [UH]), and contributed data to survival and relapse-free survival (RFS) analyses. Four-year (postnephrectomy) survival percentages and randomized treatment regimens for low-risk patients were 96.5% for 607 Stage I/FH patients who received dactinomycin (Actinomycin D [AMD], Merck Sharp & Dohme, West Point, PA) and vincristine (VCR) for 10 weeks versus 6 months; 92.2% for 278 Stage II/FH patients; and 86.9% for 275 Stage III/FH patients who received AMD + VCR +/- Adriamycin (ADR, Adria Laboratories, Columbus, OH) for 15 months. Stage II/FH patients also had either zero or 2000 cGy irradiation (RT) postoperatively and Stage III/FH patients either 1000 or 2000 cGy. Four-year survival was 73.0% for 279 high-risk patients (any Stage IV, all UH) who received postoperative radiation therapy (RT) and AMD + VCR + ADR +/- cyclophosphamide (CPM). Statistical analysis of survival and RFS experience shows that the less intensive therapy does not worsen results for low-risk patients and CPM does not benefit those at high risk.
authors.affiliation: Children's Cancer Research Center, Children's Hospital, Philadelphia, PA 19104.
authors.forename: G J
authors.initials: GJ
authors.lastname: D'Angio
authors.forename: N
authors.initials: N
authors.lastname: Breslow
authors.forename: J B
authors.initials: JB
authors.lastname: Beckwith
authors.forename: A
authors.initials: A
authors.lastname: Evans
authors.forename: H
authors.initials: H
authors.lastname: Baum
authors.forename: A
authors.initials: A
authors.lastname: deLorimier
authors.forename: D
authors.initials: D
authors.lastname: Fernbach
authors.forename: E
authors.initials: E
authors.lastname: Hrabovsky
authors.forename: B
authors.initials: B
authors.lastname: Jones
authors.forename: P
authors.initials: P
authors.lastname: Kelalis
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007680:Kidney Neoplasms / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011878:Radiotherapy / Q000009:adverse effects; D011897:Random Allocation; D009396:Wilms Tumor / Q000401:mortality / Q000628:therapy*